Advanced search
Publication Cover
Molecular and Cellular Biology Volume 20, 2000 - Issue 1
Submit an article Journal homepage
1
Views
190
CrossRef citations to date
0
Altmetric
Cell Growth and Development

The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis

Kun Jiang1 Department of Pathology
,
Domenico Coppola1 Department of Pathology
,
Nichole C. Crespo2 Drug Discovery Program and Department of Biochemistry and Molecular Biology, College of Medicine and H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida33612
,
Santo V. Nicosia1 Department of Pathology
,
Andrew D. Hamilton3 Department of Chemistry, Yale University, New Haven, Connecticut06511
,
Said M. Sebti2 Drug Discovery Program and Department of Biochemistry and Molecular Biology, College of Medicine and H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida33612Correspondence[email protected]
&
Jin Q. Cheng1 Department of PathologyCorrespondence[email protected]
 show all
Pages 139-148 | Received 21 Jun 1999, Accepted 20 Sep 1999, Published online: 28 Mar 2023

Citations (190)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (19)

Muneera Al-Hussaini & John F DiPersio. (2014) Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Review of Hematology 7:4, pages 439-464.
Read now
Nikhil G Thaker & Ian F Pollack. (2009) Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Review of Neurotherapeutics 9:12, pages 1815-1836.
Read now
Judith E Karp & Jeffrey E Lancet. (2008) Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics: Targets and Therapy 2:3, pages 491-500.
Read now
Yesid Alvarado & Francis J Giles$suffix/text()$suffix/text(). (2007) Ras as a therapeutic target in hematologic malignancies. Expert Opinion on Emerging Drugs 12:2, pages 271-284.
Read now
Elias Jabbour, Hagop Kantarjian & Jorge Cortes. (2007) Clinical activity of tipifarnib in hematologic malignancies. Expert Opinion on Investigational Drugs 16:3, pages 381-392.
Read now
Judith E. Karp & Jeffrey E. Lancet. (2007) Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies. Cancer Investigation 25:6, pages 484-494.
Read now
Floriana Morgillo & Ho-Young Lee. (2006) Lonafarnib in cancer therapy. Expert Opinion on Investigational Drugs 15:6, pages 709-719.
Read now
Elias Jabbour, Hagop Kantarjian & Jorge Cortes. (2004) Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action. Leukemia & Lymphoma 45:11, pages 2187-2195.
Read now
Nabil Saba & Fadlo Khuri. (2004) Novel targeted agents in the treatment of lung cancer. Expert Opinion on Investigational Drugs 13:6, pages 609-629.
Read now
Kun Jiang, Jiazhi Sun, Jin Cheng, Julie Y. Djeu, Sheng Wei & Saïd Sebti. (2004) Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis. Molecular and Cellular Biology 24:12, pages 5565-5576.
Read now
Julia E Head & Stephen RD Johnston. (2003) Protein farnesyltransferase inhibitors. Expert Opinion on Emerging Drugs 8:1, pages 163-178.
Read now
Lloyd R Kelland. (2003) Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opinion on Investigational Drugs 12:3, pages 413-421.
Read now
Guy Makin. (2002) Targeting apoptosis in cancer chemotherapy. Expert Opinion on Therapeutic Targets 6:1, pages 73-84.
Read now
Grace K. Dy & Alex A. Adjei. (2002) Farnesyltransferase Inhibitors in Breast Cancer Therapy. Cancer Investigation 20:sup2, pages 30-37.
Read now
Neena Rane & George C Prendergast. (2001) Farnesyltransferase inhibitors: mechanism and applications. Expert Opinion on Investigational Drugs 10:12, pages 2105-2116.
Read now
Carolyn Buser, Tohru Takaki & Laura Sepp-Lorenzino. (2001) 92nd Annual Meeting of the American Association for Cancer Research. Expert Opinion on Investigational Drugs 10:6, pages 1173-1193.
Read now
Saïd M Sebti & Andrew D Hamilton. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opinion on Investigational Drugs 9:12, pages 2767-2782.
Read now
Ian M Bell. (2000) Inhibitors of protein prenylation 2000. Expert Opinion on Therapeutic Patents 10:12, pages 1813-1831.
Read now
Ai-xue Liu, Wei Du, Jeh-Ping Liu, Thomas M. Jessell & George C. Prendergast. (2000) RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors. Molecular and Cellular Biology 20:16, pages 6105-6113.
Read now

Articles from other publishers (171)

S. G. Klochkov, M. E. Neganova & Yu. R. Aleksandrova. (2020) Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades. Russian Journal of Bioorganic Chemistry 46:6, pages 891-902.
Crossref
Khalid Jazieh, Julian Molina, Jacob Allred, Jun Yin, Joel Reid, Matthew Goetz, Vun-Sin Lim, Scott H. Kaufmann & Alex Adjei. (2018) A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational New Drugs 37:2, pages 307-314.
Crossref
Nicholas Theodosakis, Casey G. Langdon, Goran Micevic, Irina Krykbaeva, Robert E. Means, David F. Stern & Marcus W. Bosenberg. (2018) Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer . Pigment Cell & Melanoma Research 32:2, pages 292-302.
Crossref
Jingyuan Wang, Xue Yao & Jin Huang. (2017) New tricks for human farnesyltransferase inhibitor: cancer and beyond. MedChemComm 8:5, pages 841-854.
Crossref
Qiurong Wang & Jun Ren. (2016) mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1. Pharmacological Research 111, pages 357-373.
Crossref
Andreas Hentschel, René P. Zahedi & Robert Ahrends. (2016) Protein lipid modifications-More than just a greasy ballast. PROTEOMICS 16:5, pages 759-782.
Crossref
Evan J. Walker, Andrew H. Ko, Elizabeth A. Holly & Paige M. Bracci. (2015) Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study. Cancer 121:8, pages 1287-1294.
Crossref
Clovis O Da Fonseca & Thereza Quirico-Santos. 2015. Bioactive Essential Oils and Cancer. Bioactive Essential Oils and Cancer 267 288 .
Jennifer L. Larson-Casey, Shubha Murthy, Alan J. Ryan & A. Brent Carter. (2014) Modulation of the Mevalonate Pathway by Akt Regulates Macrophage Survival and Development of Pulmonary Fibrosis. Journal of Biological Chemistry 289:52, pages 36204-36219.
Crossref
Wenying Ren, Sarwat Cheema & Keyong Du. (2012) The Association of ClipR-59 Protein with AS160 Modulates AS160 Protein Phosphorylation and Adipocyte Glut4 Protein Membrane Translocation. Journal of Biological Chemistry 287:32, pages 26890-26900.
Crossref
Sannu A. Thomas, Reshma Thamkachy, Bindu Ashokan, Reena J. Komalam, Keerthi V. Sreerekha, Asha Bharathan, Thankayyan R. Santhoshkumar, Kallikat N. Rajasekharan & Suparna Sengupta. (2012) Diaminothiazoles Inhibit Angiogenesis Efficiently by Suppressing Akt Phosphorylation. Journal of Pharmacology and Experimental Therapeutics 341:3, pages 718-724.
Crossref
Claudia Nitsche, Mouad Edderkaoui, Ryan M. Moore, Guido Eibl, Noriyuki Kasahara, Janet Treger, Paul J. Grippo, Julia Mayerle, Markus M. Lerch & Anna S. Gukovskaya. (2012) The Phosphatase PHLPP1 Regulates Akt2, Promotes Pancreatic Cancer Cell Death, and Inhibits Tumor Formation. Gastroenterology 142:2, pages 377-387.e5.
Crossref
Alina Ghinet, Benoît Rigo, Joëlle Dubois, Amaury Farce, Jean-Pierre Hénichart & Philippe Gautret. (2012) Discovery of ferrocene-containing farnesyltransferase inhibitors. Investigation of bulky lipophilic groups for the A2 binding site of farnesyltransferase. MedChemComm 3:9, pages 1147.
Crossref
Qiaojia Huang, Fenghua Lan, Zhiyong Zheng, Feilai Xie, Junyong Han, Lihong Dong, Yanchuan Xie & Feng Zheng. (2011) Akt2 Kinase Suppresses Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)-mediated Apoptosis in Ovarian Cancer Cells via Phosphorylating GAPDH at Threonine 237 and Decreasing Its Nuclear Translocation. Journal of Biological Chemistry 286:49, pages 42211-42220.
Crossref
Thomas E. Witzig, Hui TangIvana N. M. Micallef, Stephen M. Ansell, Brian K. LinkDavid J. Inwards, Luis F. Porrata, Patrick B. Johnston, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Carrie A. Thompson, Cristine AllmerMatthew J. MaurerMamta Gupta, George WeinerRay HohlPaul J. Kurtin, Husheng Ding, David Loegering, Paula Schneider, Kevin Peterson, Thomas M. Habermann & Scott H. Kaufmann. (2011) Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 118:18, pages 4882-4889.
Crossref
Husheng Ding, Jennifer Hackbarth, Paula A. Schneider, Kevin L. Peterson, X. Wei Meng, Haiming Dai, Thomas E. Witzig & Scott H. Kaufmann. (2011) Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 118:18, pages 4872-4881.
Crossref
Norbert Berndt, Andrew D. Hamilton & Saïd M. Sebti. (2011) Targeting protein prenylation for cancer therapy. Nature Reviews Cancer 11:11, pages 775-791.
Crossref
Laura A. Genovesi, Kim W. Carter, Nicholas G. Gottardo, Keith M. Giles & Peter B. Dallas. (2011) Integrated Analysis of miRNA and mRNA Expression in Childhood Medulloblastoma Compared with Neural Stem Cells. PLoS ONE 6:9, pages e23935.
Crossref
Niranjan Yanamandra, Robert W. Buzzeo, Mark Gabriel, Lori A. Hazlehurst, Yelenis Mari, Darrin M. Beaupre & Javier Cuevas. (2011) Tipifarnib-Induced Apoptosis in Acute Myeloid Leukemia and Multiple Myeloma Cells Depends on Ca 2+ Influx through Plasma Membrane Ca 2+ Channels . Journal of Pharmacology and Experimental Therapeutics 337:3, pages 636-643.
Crossref
Maria E. Balasis, Kara D. Forinash, Y. Ann Chen, William J. Fulp, Domenico Coppola, Andrew D. Hamilton, Jin Q. Cheng & Saïd M. Sebti. (2011) Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice. Clinical Cancer Research 17:9, pages 2852-2862.
Crossref
Jeffrey E. Lancet, Vu H. Duong, Elliott F. Winton, Robert K. Stuart, Michelle Burton, Shumin Zhang, Christopher Cubitt, Michelle A. Blaskovich, John J. Wright, Said Sebti & Daniel M. Sullivan. (2011) A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias. Clinical Cancer Research 17:5, pages 1140-1146.
Crossref
Norbert Berndt, Andrew D. Hamilton & Saïd M. Sebti. 2011. Protein Prenylation Part B. Protein Prenylation Part B 129 163 .
Shuzhen Chen, Lei Fu, Shruti M Raja, Ping Yue, Fadlo R Khuri & Shi-Yong Sun. (2010) Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Molecular Cancer 9:1.
Crossref
Kerri L. Chock, Jamie M.S. Allison, Yoshiko Shimizu & Wael M. ElShamy. (2010) BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells. Cancer Research 70:21, pages 8782-8791.
Crossref
Donghwa Kim, Mei Sun, Lili He, Qing-Hua Zhou, Jun Chen, Xia-Meng Sun, Gerold Bepler, Said M. Sebti & Jin Q. Cheng. (2010) A Small Molecule Inhibits Akt through Direct Binding to Akt and Preventing Akt Membrane Translocation. Journal of Biological Chemistry 285:11, pages 8383-8394.
Crossref
Ming-Chieh Shun, Weiping Yu, Sook-Kyung Park, Bob G. Sanders & Kimberly Kline. (2010) Downregulation of Epidermal Growth Factor Receptor Expression Contributes to -TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines . Journal of Oncology 2010, pages 1-11.
Crossref
James J. Fiordalisi & Adrienne D. Cox. 2010. Handbook of Cell Signaling. Handbook of Cell Signaling 1819 1826 .
Ian F. Pollack. 2010. Molecularly Targeted Therapy for Childhood Cancer. Molecularly Targeted Therapy for Childhood Cancer 231 265 .
Judith E. KarpKaren FlattenEric J. FeldmanJacqueline M. GreerDavid A. LoegeringRebecca M. RicklisLawrence E. MorrisEllen RitchieB. Douglas SmithValerie IronsideTimothy TalbottGail RobozSon B. LeXue Wei MengPaula A. SchneiderNga T. DaiAlex A. AdjeiSteven D. GoreMark J. LevisJohn J. Wright, Elizabeth Garrett-Mayer & Scott H. Kaufmann. (2009) Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 113:20, pages 4841-4852.
Crossref
Sun Joo Lee & Chung Soo Lee. (2008) Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells. Naunyn-Schmiedeberg's Archives of Pharmacology 379:3, pages 291-303.
Crossref
Ioannis KotsianidisEvangelia NakouIrene Bouchliou. (2009) Pharmacotherapy of Hematologic Malignancies with Tipifarnib. Clinical Medicine. Therapeutics 1, pages CMT.S1097.
Crossref
Changkun Hu, V. Raja Solomon, Gerardo Ulibarri & Hoyun Lee. (2008) The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorganic & Medicinal Chemistry 16:17, pages 7888-7893.
Crossref
Thorsten Braun & Pierre Fenaux. (2008) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology 141:5, pages 576-586.
Crossref
Seung Hyun Oh, Quanri Jin, Edward S. Kim, Fadlo R. Khuri & Ho-Young Lee. (2008) Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression. Clinical Cancer Research 14:5, pages 1581-1589.
Crossref
Hong-Gang Yu, Yao-Wei Ai, Liang-Liang Yu, Xiao-Dong Zhou, Jin Liu, Jun-Hua Li, Xi-Ming Xu, Song Liu, Jing Chen, Fen Liu, Yuan-Ling Qi, Quanjun Deng, Jun Cao, Shi-Quan Liu, He-Sheng Luo & Jie-Ping Yu. (2008) Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. International Journal of Cancer 122:2, pages 433-443.
Crossref
R. Donald Harvey, Jeannine Silberman & Sagar Lonial. 2009. Myeloma Therapy. Myeloma Therapy 309 322 .
Alison H.M. Reid, Richard Baird & Paul Workman. 2008. Principles of Molecular Oncology. Principles of Molecular Oncology 317 365 .
R Donald HarveySagar Lonial. (2007) PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncology 3:6, pages 639-647.
Crossref
Maryam Fouladi, H. Stacy Nicholson, Tianni Zhou, Fred Laningham, Kathleen J. Helton, Emi Holmes, Kenneth Cohen, Rose Anne Speights, John Wright & Ian F. Pollack. (2007) A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: A children's oncology group study. Cancer 110:11, pages 2535-2541.
Crossref
Pauline Gilleron, Nicolas Wlodarczyk, Raymond Houssin, Amaury Farce, Guillaume Laconde, Jean-François Goossens, Amélie Lemoine, Nicole Pommery, Jean-Pierre Hénichart & Régis Millet. (2007) Design, synthesis and biological evaluation of substituted dioxodibenzothiazepines and dibenzocycloheptanes as farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:19, pages 5465-5471.
Crossref
Takuji Miyoshi, Tadashi Nagai, Satoru Kikuchi, Ken Ohmine, Makiko Nakamura, Toshiaki Hanafusa, Norio Komatsu & Keiya Ozawa. (2007) Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib. Experimental Hematology 35:9, pages 1358-1365.
Crossref
Arezu Jahani-Asl, Ajoy Basak & Benjamin K. Tsang. (2007) Caspase-3-mediated cleavage of Akt: Involvement of non-consensus sites and influence of phosphorylation. FEBS Letters 581:16, pages 2883-2888.
Crossref
Shi-Yong Sun, Xiangguo Liu, Wei Zou, Ping Yue, Adam I. Marcus & Fadlo R. Khuri. (2007) The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells. Journal of Biological Chemistry 282:26, pages 18800-18809.
Crossref
Yuanzheng Qiu, Xiangguo Liu, Wei Zou, Ping Yue, Sagar Lonial, Fadlo R. Khuri & Shi-Yong Sun. (2007) The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells. Cancer Research 67:10, pages 4973-4980.
Crossref
Monica R. Maiello, Amelia D’Alessio, Antonella De Luca, Adele Carotenuto, Anna Maria Rachiglio, Maria Napolitano, Letizia Cito, Antonella Guzzo & Nicola Normanno. (2006) AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Research and Treatment 102:3, pages 275-282.
Crossref
Mitch Raponi, Jean-Luc Harousseau, Jeffrey E. Lancet, Bob Löwenberg, Richard Stone, Yi Zhang, Wayne Rackoff, Yixin Wang & David Atkins. (2007) Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research 13:7, pages 2254-2260.
Crossref
B C Medeiros, H J Landau, M Morrow, R O Lockerbie, T Pitts & S G Eckhardt. (2007) The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 21:4, pages 739-746.
Crossref
E. Zhuravliova, T. Barbakadze, N. Narmania, J. Ramsden & D. Mikeladze. (2007) Inhibition of nitric oxide synthase and farnesyltransferase change the activities of several transcription factors. Journal of Molecular Neuroscience 31:3, pages 281-287.
Crossref
Athanasios G. Papatsoris, Michalis V. Karamouzis & Athanasios G. Papavassiliou. (2007) The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics. Molecular Cancer Therapeutics 6:3, pages 811-819.
Crossref
P. Fumoleau, M. Campone, B. Coudert, F. Mayer, L. Favier & E. Ferrant. 2007. Cancer du sein. Cancer du sein 453 498 .
Jeffrey E. Lancet. 2007. Acute Myelogenous Leukemia. Acute Myelogenous Leukemia 263 274 .
Debra L. Smith, Laura K. Nolden, Gordon B. Mills & Yiling Lu. 2007. Apoptosis, Senescence, and Cancer. Apoptosis, Senescence, and Cancer 313 334 .
Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia & Jin Q. Cheng. (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. International Journal of Cancer 119:10, pages 2304-2312.
Crossref
D. CILLONI, E. MESSA, F. MESSA, S. CARTURAN, I. DEFILIPPI, F. ARRUGA, V. ROSSO, R. CATALANO, E. BRACCO, P. NICOLI & G. SAGLIO. (2006) Genetic Abnormalities as Targets for Molecular Therapies in Myelodysplastic Syndromes. Annals of the New York Academy of Sciences 1089:1, pages 411-423.
Crossref
L. Gore, S.N. Holden, R.B. Cohen, M. Morrow, A.S. Pierson, C.L. O'Bryant, M. Persky, D. Gustafson, C. Mikule, S. Zhang, P.A. Palmer & S.G. Eckhardt. (2006) A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Annals of Oncology 17:11, pages 1709-1717.
Crossref
Yupeng Wang, Bing Su & Zhengui Xia. (2006) Brain-derived Neurotrophic Factor Activates ERK5 in Cortical Neurons via a Rap1-MEKK2 Signaling Cascade. Journal of Biological Chemistry 281:47, pages 35965-35974.
Crossref
Wandena S. Siegel-Lakhai, Mirjam Crul, Peter De Porre, Steven Zhang, Ilsung Chang, Henk Boot, Jos H. Beijnen & Jan H.M. Schellens. (2006) Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function. Journal of Clinical Oncology 24:28, pages 4558-4564.
Crossref
Yu-An Zhang, John Nemunaitis, Shirley K. Samuel, Patrick Chen, Yuqiao Shen & Alex W. Tong. (2006) Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA. Cancer Research 66:19, pages 9736-9743.
Crossref
Wolfgang Benetka, Manfred Koranda & Frank Eisenhaber. (2006) Protein Prenylation: An (Almost) Comprehensive Overview on Discovery History, Enzymology, and Significance in Physiology and Disease. Monatshefte für Chemie - Chemical Monthly 137:10, pages 1241-1281.
Crossref
Hui-Chiu Chang, Chun-Yu Cho & Wen-Chun Hung. (2006) Silencing of the Metastasis Suppressor RECK by RAS Oncogene Is Mediated by DNA Methyltransferase 3b–Induced Promoter Methylation. Cancer Research 66:17, pages 8413-8420.
Crossref
P. Gilleron, R. Millet, R. Houssin, N. Wlodarczyk, A. Farce, A. Lemoine, J.-F. Goossens, P. Chavatte, N. Pommery & J.-P. Hénichart. (2006) Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds. European Journal of Medicinal Chemistry 41:6, pages 745-755.
Crossref
Gen Wang, John W. Barrett, Marianne Stanford, Steven J. Werden, James B. Johnston, Xiujuan Gao, Mei Sun, Jin Q. Cheng & Grant McFadden. (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proceedings of the National Academy of Sciences 103:12, pages 4640-4645.
Crossref
M Huang, U Kamasani & G C Prendergast. (2005) RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene 25:9, pages 1281-1289.
Crossref
Aarne Fleischer, Ata Ghadiri, Frédéric Dessauge, Marianne Duhamel, Maria Paz Rebollo, Fernando Alvarez-Franco & Angelita Rebollo. (2006) Modulating apoptosis as a target for effective therapy. Molecular Immunology 43:8, pages 1065-1079.
Crossref
U K Khanzada, O E Pardo, C Meier, J Downward, M J Seckl & A Arcaro. (2005) Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 25:6, pages 877-887.
Crossref
Clovis Orlando da Fonseca, José Alberto Landeiro, Steven S. Clark, Thereza Quirico-Santos, Maria da Gloria da Costa Carvalho & Cerli Rocha Gattass. (2006) Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surgical Neurology 65, pages S2-S8.
Crossref
Andrea D. Basso, Paul Kirschmeier & W. Robert Bishop. (2006) Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors. Journal of Lipid Research 47:1, pages 15-31.
Crossref
Gurpreet S. Kapoor & Donald M. O’Rourke. 2006. The Cell Cycle in the Central Nervous System. The Cell Cycle in the Central Nervous System 389 417 .
D. W. End, L. Mevellec & P. Angibaud. 2007. Cancer. Cancer 133 168 .
P. Fumoleau, M. Campone, N. Isambert, E. Bourbouloux, F. Mayer & B. Coudert. 2006. Cancer du sein. Cancer du sein 233 266 .
Judith E KarpJeffrey E Lancet. (2005) Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Future Oncology 1:6, pages 719-731.
Crossref
Jin Q Cheng, Craig W Lindsley, George Z Cheng, Hua Yang & Santo V Nicosia. (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24:50, pages 7482-7492.
Crossref
W S Siegel-Lakhai, M Crul, S Zhang, R W Sparidans, D Pluim, A Howes, B Solanki, J H Beijnen & J H M Schellens. (2005) Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British Journal of Cancer 93:11, pages 1222-1229.
Crossref
Natalie M.G.M. Appels, Jos H. Beijnen & Jan H.M. Schellens. (2005) Development of Farnesyl Transferase Inhibitors: A Review. The Oncologist 10:8, pages 565-578.
Crossref
Miyako Yanagihara, Masayoshi Katano, Noriko Takahashi-Sasaki, Kiyonori Kimata, Kazunari Taira & Toshiwo Andoh. (2005) Ribozymes targeting serine/threonine kinase Akt1 sensitize cells to anticancer drugs. Cancer Science 96:9, pages 620-626.
Crossref
Robert Buzzeo, Steven Enkemann, Rama Nimmanapalli, Melissa Alsina, Mathias G. Lichtenheld, William S. Dalton & Darrin M. Beaupre. (2005) Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341. Clinical Cancer Research 11:16, pages 6057-6064.
Crossref
Alex A. Adjei & Manuel Hidalgo. (2005) Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. Journal of Clinical Oncology 23:23, pages 5386-5403.
Crossref
Laura M. Bruzek, Jenny N. Poynter, Scott H. Kaufmann & Alex A. Adjei. (2005) Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5 H -benzo-(5,6)-cyclohepta(1,2- b )-pyridin-11( R )-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336) . Molecular Pharmacology 68:2, pages 477-486.
Crossref
Kuichun ZhuElvira GerbinoDarrin M. BeauprePaul A. MackleyCarlos Muro-CachoCraig BeamAndrew D. HamiltonMathias G. LichtenheldWilliam G. KerrWilliam DaltonMelissa AlsinaSaïd M. Sebti. (2005) Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105:12, pages 4759-4766.
Crossref
Jingxuan Pan, Miaorong She, Zhi-Xiang Xu, Lily Sun & Sai-Ching Jim Yeung. (2005) Farnesyltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells. Cancer Research 65:9, pages 3671-3681.
Crossref
G. Gasparini, R. Longo, F. Torino & A. Morabito. (2005) Therapy of breast cancer with molecular targeting agents. Annals of Oncology 16, pages iv28-iv36.
Crossref
Debra Ferguson, Luis E. Rodriguez, Joann P. Palma, Marion Refici, Kenneth Jarvis, Jacqueline O'Connor, Gerard M. Sullivan, David Frost, Kennan Marsh, Joy Bauch, Haiying Zhang, Nan-Horng Lin, Saul Rosenberg, Hing L. Sham & Ingrid B.J.K. Joseph. (2005) Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models. Clinical Cancer Research 11:8, pages 3045-3054.
Crossref
Josep Tabernero, Fredy Rojo, Irene Marimón, Maurizio Voi, Joan Albanell, Marta Guix, Federico Vázquez, Joan Carulla, Michael Cooper, Jordi Andreu, Anne Van Vreckem, Joaquim Bellmunt, Veeraswamy Manne, James A. Manning, Carmen Garrido, Enriqueta Felip, Josep Maria del Campo, Mónica García, Sonia Valverde & José Baselga. (2005) Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 23:11, pages 2521-2533.
Crossref
Niketa A. Patel, Satoshi Kaneko, Hercules S. Apostolatos, Sun Sik Bae, James E. Watson, Karen Davidowitz, David S. Chappell, Morris J. Birnbaum, Jin Q. Cheng & Denise R. Cooper. (2005) Molecular and Genetic Studies Imply Akt-mediated Signaling Promotes Protein Kinase CβII Alternative Splicing via Phosphorylation of Serine/Arginine-rich Splicing Factor SRp40. Journal of Biological Chemistry 280:14, pages 14302-14309.
Crossref
Bart Cornelissen, Christophe Lahorte, Veerle Kersemans, Gabriela Capriotti, Elena Bonanno, Alberto Signore, Christophe Van de Wiele, Rudi A. Dierckx & Guido Slegers. (2005) In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. Nuclear Medicine and Biology 32:3, pages 233-239.
Crossref
Saïd M. Sebti. (2005) Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7:4, pages 297-300.
Crossref
Mark R. Lackner, Rachel M. Kindt, Pamela M. Carroll, Katherine Brown, Michael R. Cancilla, Changyou Chen, Heshani de Silva, Yvonne Franke, Bo Guan, Tim Heuer, Tak Hung, Kevin Keegan, Jae Moon Lee, Veeraswamy Manne, Carol O’Brien, Dianne Parry, Juan J. Perez-Villar, Rajashekar K. Reddy, Hong Xiao, Hangjun Zhan, Mark Cockett, Greg Plowman, Kevin Fitzgerald, Michael Costa & Petra Ross-Macdonald. (2005) Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7:4, pages 325-336.
Crossref
Alex A. Adjei. 2005. 123 133 .
Ph. Cestac, S. Doisneau-Sixou & G. Favre. (2005) Développement des inhibiteurs de farnésyl transférase comme agents anticancéreux. Annales Pharmaceutiques Françaises 63:1, pages 76-84.
Crossref
Todd M. Zimmerman, Helena Harlin, Olatoyosi M. Odenike, Seth Berk, Evie Sprague, Theodore Karrison, Wendy Stock, Richard A. Larson, Mark J. Ratain & Thomas F. Gajewski. (2004) Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies. Journal of Clinical Oncology 22:23, pages 4816-4822.
Crossref
Julia Head & Stephen RD Johnston. (2004) New targets for therapy in breast cancer: Farnesyltransferase inhibitors. Breast Cancer Research 6:6.
Crossref
Mitch Raponi, Robert T Belly, Judith E Karp, Jeffrey E Lancet, David Atkins & Yixin Wang. (2004) Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4:1.
Crossref
Steven D. Gore. (2004) Inhibitors of signaling in myelodysplastic syndrome. Best Practice & Research Clinical Haematology 17:4, pages 613-622.
Crossref
H.-Y. Lee, H. Moon, K.-H. Chun, Y.-S. Chang, K. Hassan, L. Ji, R. Lotan, F. R. Khuri & W. K. Hong. (2004) Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells. JNCI Journal of the National Cancer Institute 96:20, pages 1536-1548.
Crossref
Geneviève Dufour, Marie-Josée Demers, David Gagné, Anders Bondo Dydensborg, Inga C. Teller, Véronique Bouchard, Isabelle Degongre, Jean-François Beaulieu, Jin Q. Cheng, Naoya Fujita, Takashi Tsuruo, Karine Vallée & Pierre H. Vachon. (2004) Human Intestinal Epithelial Cell Survival and Anoikis. Journal of Biological Chemistry 279:42, pages 44113-44122.
Crossref
I Marzo, P Pérez-Galán, P Giraldo, N López-Royuela, M Gómez-Benito, L Larrad, P Lasierra, D Rubio-Félix, A Anel & J Naval. (2004) Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:10, pages 1599-1604.
Crossref
Lin Yang, Han C. Dan, Mei Sun, Qiyuan Liu, Xia-meng Sun, Richard I. Feldman, Andrew D. Hamilton, Mark Polokoff, Santo V. Nicosia, Meenhard Herlyn, Said M. Sebti & Jin Q. Cheng. (2004) Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt. Cancer Research 64:13, pages 4394-4399.
Crossref
Bruce E. Johnson & John V. Heymach. (2004) Farnesyl Transferase Inhibitors for Patients with Lung Cancer. Clinical Cancer Research 10:12, pages 4254s-4257s.
Crossref
Veeraswamy Manne, Francis Y. F. Lee, David K. Bol, Johnni Gullo-Brown, Craig R. Fairchild, Louis J. Lombardo, Richard A. Smykla, Gregory D. Vite, Mei-Li D. Wen, Chiang Yu, Tai Wai Wong & John T. Hunt. (2004) Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models. Cancer Research 64:11, pages 3974-3980.
Crossref
E. Van CutsemH. van de VeldeP. KarasekH. OettleW.L. VervenneA. SzawlowskiP. SchoffskiS. PostC. VerslypeH. NeumannH. SafranY. HumbletJ. Perez RuixoY. MaD. Von Hoff. (2004) Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. Journal of Clinical Oncology 22:8, pages 1430-1438.
Crossref
Helen J. Mackay, Ronald Hoekstra, Ferry A. L. M. Eskens, Walker J. Loos, Donna Crawford, Maurizio Voi, Anne Van Vreckem, T. R. Jeffrey Evans & Jaap Verweij. (2004) A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research 10:8, pages 2636-2644.
Crossref
David P. Ryan, Joseph P. EderJr.Jr., Thomas Puchlaski, Michael V. Seiden, Thomas J. Lynch, Charles S. Fuchs, Philip C. Amrein, Darrell Sonnichsen, Jeffrey G. Supko & Jeffrey W. Clark. (2004) Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors. Clinical Cancer Research 10:7, pages 2222-2230.
Crossref
Julien Mazieres, Anne Pradines & Gilles Favre. (2004) Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Letters 206:2, pages 159-167.
Crossref
Said M Sebti & Alex A Adjei. (2004) Farnesyltransferase inhibitors. Seminars in Oncology 31, pages 28-39.
Crossref
S Zhao, M Konopleva, M Cabreira-Hansen, Z Xie, W Hu, M Milella, Z Estrov, G B Mills & M Andreeff. (2003) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18:2, pages 267-275.
Crossref
Han C Dan, Kun Jiang, Domenico Coppola, Andrew Hamilton, Santo V Nicosia, Said M Sebti & Jin Q Cheng. (2004) Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23:3, pages 706-715.
Crossref
MICHAEL FRASER & BENJAMIN K. TSANG. 2004. The Ovary. The Ovary 613 624 .
C. D. Johnson & C. W. ImrieHelgi van de Velde, Vanina Popova, Irina Mountian & Peter de Porre. 2004. Pancreatic Disease. Pancreatic Disease 79 92 .
Nancy E. Kohl. 2004. Cancer Chemoprevention. Cancer Chemoprevention 303 316 .
Razelle KurzrockHagop M. KantarjianJorge E. CortesNeil SinghaniaDeborah A. ThomasEdward F. WilsonJohn J. WrightEmil J. FreireichMoshe TalpazSaïd M. Sebti. (2003) Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102:13, pages 4527-4534.
Crossref
Saïd M. Sebti. (2003) Blocked Pathways: FTIs Shut Down Oncogene Signals. The Oncologist 8:S3, pages 30-38.
Crossref
Jeffrey E. LancetJudith E. Karp. (2003) Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102:12, pages 3880-3889.
Crossref
Saïd M. Sebti & Channing J. Der. (2003) Searching for the elusive targets of farnesyltransferase inhibitors. Nature Reviews Cancer 3:12, pages 945-951.
Crossref
H. T. See, J. J. Kavanagh, W. Hu & R. C. Bast. (2003) Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer 13:6, pages 701-734.
Crossref
Irit Adini, Isaac Rabinovitz, Jing Fang Sun, George C. Prendergast & Laura E. Benjamin. (2003) RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes & Development 17:21, pages 2721-2732.
Crossref
Mei Sun, Lin Yang, Richard I. Feldman, Xia-meng Sun, Kapil N. Bhalla, Richard Jove, Santo V. Nicosia & Jin Q. Cheng. (2003) Activation of Phosphatidylinositol 3-Kinase/Akt Pathway by Androgen through Interaction of p85α, Androgen Receptor, and Src. Journal of Biological Chemistry 278:44, pages 42992-43000.
Crossref
Shozo Nishida, Yoshiki Fujii, Shohei Yoshioka, Sigeru Kikuichi, Masanobu Tsubaki & Kiyohiro Irimajiri. (2003) A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sciences 73:21, pages 2655-2664.
Crossref
Zhongqiu Zhang, Yian Wang, Laura E Lantry, Elizabeth Kastens, Gongjie Liu, Andrew D Hamilton, Said M Sebti, Ronald A Lubet & Ming You. (2003) Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene 22:40, pages 6257-6265.
Crossref
Rodrigo SantucciPaul A. Mackley, Saïd Sebti & Melissa Alsina. (2017) Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma. Cancer Control 10:5, pages 384-387.
Crossref
J L Liesveld, J E Lancet, K E Rosell, A Menon, C Lu, C McNairIIII, C N Abboud & J D Rosenblatt. (2003) Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia 17:9, pages 1806-1812.
Crossref
M A Morgan, A Ganser & C W M Reuter. (2003) Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 17:8, pages 1482-1498.
Crossref
Santo V Nicosia, Wenlong Bai, Jin Q Cheng, Domenico Coppola & Patricia A Kruk. (2003) Oncogenic pathways implicated in ovarian epithelial cancer. Hematology/Oncology Clinics of North America 17:4, pages 927-943.
Crossref
Alex A Adjei. (2003) An overview of farnesyltransferase inhibitors and their role in lung cancer therapy. Lung Cancer 41, pages 55-62.
Crossref
Brigette B.Y. MaRobert G. BristowJohn KimLillian L. Siu. (2003) Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents. Journal of Clinical Oncology 21:14, pages 2760-2776.
Crossref
Zeng-qiang Yuan, Richard I. Feldman, Gene E. Sussman, Domenico Coppola, Santo V. Nicosia & Jin Q. Cheng. (2003) AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1. Journal of Biological Chemistry 278:26, pages 23432-23440.
Crossref
Alex A. AdjeiAnn MauerLaura BruzekRandolph S. MarksShauna HillmanSusan GeyerLorelei J. HansonJohn J. WrightCharles ErlichmanScott H. KaufmannEverett E. Vokes. (2003) Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 21:9, pages 1760-1766.
Crossref
F Chang, J T Lee, P M Navolanic, L S Steelman, J G Shelton, W L Blalock, R A Franklin & J A McCubrey. (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:3, pages 590-603.
Crossref
Chad A. Ellis, Michele D. Vos, Meredith Wickline, Christine Riley, Teresa Vallecorsa, William G. Telford, JoAnne Zujewski & Geoffrey J. Clark. (2003) Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines. Breast Cancer Research and Treatment 78:1, pages 59-67.
Crossref
Julien Mazières, Anne Pradines & Gilles Favre. (2003) Les inhibiteurs de farnésyl transférase : une cible peut en cacher une autre. médecine/sciences 19:2, pages 211-216.
Crossref
C Fiorentini, L Falzano, S Travaglione & A Fabbri. (2003) Hijacking Rho GTPases by protein toxins and apoptosis: molecular strategies of pathogenic bacteria. Cell Death & Differentiation 10:2, pages 147-152.
Crossref
Paul S. Mischel & Timothy F. Cloughesy. (2006) Targeted Molecular Therapy of GBM. Brain Pathology 13:1, pages 52-61.
Crossref
Alex A. Adjei. 2003. 127 144 .
James J. Fiordalisi & Adrienne D. Cox. 2003. Handbook of Cell Signaling. Handbook of Cell Signaling 737 744 .
Sean L. O’Connor, Fermin Briones, Nikhil S. Chari, Song H. Cho, Rebecca L. Hamm, Yoshihiko Kadowaki, Sangjun Lee, Kevin B. Spurgers & Timothy J. McDonnell. 2003. Essentials of Apoptosis. Essentials of Apoptosis 177 199 .
Kip A West, S Sianna Castillo & Phillip A Dennis. (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates 5:6, pages 234-248.
Crossref
Irene M Ghobrial & Alex A Adjei. (2002) Inhibitors of the ras oncogene as therapeutic targets. Hematology/Oncology Clinics of North America 16:5, pages 1065-1088.
Crossref
Han C. Dan, Mei Sun, Lin Yang, Richard I. Feldman, Xue-Mei Sui, Chien Chen Ou, Mark Nellist, Raymond S. Yeung, Dicky J.J. Halley, Santo V. Nicosia, Warren J. Pledger & Jin Q. Cheng. (2002) Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Tuberous Sclerosis Tumor Suppressor Complex by Phosphorylation of Tuberin. Journal of Biological Chemistry 277:38, pages 35364-35370.
Crossref
S Le Gouill, C Pellat-Deceunynck, J-L Harousseau, M-J Rapp, N Robillard, R Bataille & M Amiot. (2002) Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16:9, pages 1664-1667.
Crossref
P Haluska, G.K Dy & A.A Adjei. (2002) Farnesyl transferase inhibitors as anticancer agents. European Journal of Cancer 38:13, pages 1685-1700.
Crossref
Zeng-qiang Yuan, Richard I. Feldman, Mei Sun, Nancy E. Olashaw, Domenico Coppola, Gene E. Sussman, Sue A. Shelley, Santo V. Nicosia & Jin Q. Cheng. (2002) Inhibition of JNK by Cellular Stress- and Tumor Necrosis Factor α-induced AKT2 through Activation of the NFκB Pathway in Human Epithelial Cells. Journal of Biological Chemistry 277:33, pages 29973-29983.
Crossref
Razelle Kurzrock. (2002) Myelodysplastic syndrome overview. Seminars in Hematology 39:3, pages 18-25.
Crossref
Jin Q Cheng, Xiuxian Jiang, Michael Fraser, Ming Li, Han C Dan, Mei Sun & Benjamin K Tsang. (2002) Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resistance Updates 5:3-4, pages 131-146.
Crossref
JT Lee Jr & JA McCubrey. (2002) The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16:4, pages 486-507.
Crossref
Keiran S.M. Smalley & Tim G. Eisen. (2002) Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. International Journal of Cancer 98:4, pages 514-522.
Crossref
Carlos L Arteaga, Fadlo Khuri, Geoffrey Krystal & Said Sebti. (2002) Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology 29:1, pages 15-26.
Crossref
George C. Prendergast. 2002. Tumor Suppressing Viruses, Genes, and Drugs. Tumor Suppressing Viruses, Genes, and Drugs 293 309 .
Adrienne D. Cox & L. Gerard ToussaintIIIIII. 2002. Pancreatic Cancer. Pancreatic Cancer 389 395 .
Y Fujio, Y Mitsuuchi, J R Testa & K Walsh. (2001) Activation of Akt2 Inhibits anoikis and apoptosis induced by myogenic differentiation. Cell Death & Differentiation 8:12, pages 1207-1212.
Crossref
Judith E. Karp, Scott H. Kaufmann, Alex A. Adjei, Jeffrey E. Lancet, John J. Wright & David W. End. (2001) Current status of clinical trials of farnesyltransferase inhibitors. Current Opinion in Oncology 13:6, pages 470-476.
Crossref
George C. Prendergast. (2001) Actin' up: RhoB in cancer and apoptosis. Nature Reviews Cancer 1:2, pages 162-168.
Crossref
Yusuke Mizukami, Hitoshi Ura, Takeshi Obara, Atsuya Habiro, Tsutomu Izawa, Manabu Osanai, Nobuyuki Yanagawa, Satoshi Tanno & Yutaka Kohgo. (2001) Requirement of c-Jun N-Terminal Kinase for Apoptotic Cell Death Induced by Farnesyltransferase Inhibitor, Farnesylamine, in Human Pancreatic Cancer Cells. Biochemical and Biophysical Research Communications 288:1, pages 198-204.
Crossref
Mei Sun, Gen Wang, June E. Paciga, Richard I. Feldman, Zeng-Qiang Yuan, Xiao-Ling Ma, Sue A. Shelley, Richard Jove, Philip N. Tsichlis, Santo V. Nicosia & Jin Q. Cheng. (2001) AKT1/PKBα Kinase Is Frequently Elevated in Human Cancers and Its Constitutive Activation Is Required for Oncogenic Transformation in NIH3T3 Cells. The American Journal of Pathology 159:2, pages 431-437.
Crossref
A. A. Adjei. (2001) Blocking Oncogenic Ras Signaling for Cancer Therapy. JNCI Journal of the National Cancer Institute 93:14, pages 1062-1074.
Crossref
Michelle Y. Alfonso-De Matte, Jin Q. Cheng & Patricia A. Kruk. (2001) Ultraviolet Irradiation- and Dimethyl Sulfoxide-Induced Telomerase Activity in Ovarian Epithelial Cell Lines. Experimental Cell Research 267:1, pages 13-27.
Crossref
Judith E. KarpJeffrey E. LancetScott H. KaufmannDavid W. EndJohn J. WrightKees BolIvan HorakMichael L. TidwellJane LiesveldTimothy J. KottkeDawn AngeLaxmi BuddharajuIvana GojoW. Edward HighsmithRobert T. BellyRaymond J. HohlMary Ellen RybakAlain ThibaultJoseph Rosenblatt. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97:11, pages 3361-3369.
Crossref
Hongmiao Sheng, Jinyi Shao, M. Kay Washington & Raymond N. DuBois. (2001) Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma Cells. Journal of Biological Chemistry 276:21, pages 18075-18081.
Crossref
Nichole C. Crespo, Junko Ohkanda, Tim J. Yen, Andrew D. Hamilton & Saı̈d M. Sebti. (2001) The Farnesyltransferase Inhibitor, FTI-2153, Blocks Bipolar Spindle Formation and Chromosome Alignment and Causes Prometaphase Accumulation during Mitosis of Human Lung Cancer Cells. Journal of Biological Chemistry 276:19, pages 16161-16167.
Crossref
Arthur M. Mercurio, Robin E. Bachelder, Isaac Rabinovitz, Kathleen L. O’Connor, Taneli Tani & Leslie M. Shaw. (2001) The Metastatic Odyssey. Surgical Oncology Clinics of North America 10:2, pages 313-328.
Crossref
Grégoire P. Prevost, Anne Pradines, Marie-Christine Brezak, Marie-Odile Lonchampt, Isabelle Viossat, Isabelle Ader, Christine Toulas, Philip Kasprzyk, Thomas Gordon, Gilles Favre & Barry Morgan. (2001) Inhibition of human tumor cell growthin vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. International Journal of Cancer 91:5, pages 718-722.
Crossref
Adrienne D. Cox. (2001) Farnesyltransferase Inhibitors. Drugs 61:6, pages 723-732.
Crossref
Xuesong Liu, Yan Shi, Edward K.-H. Han, Zehan Chen, Saul H. Rosenberg, Vincent L. Giranda, Yan Luo & Shi-Chung Ng. (2001) Downregulation of Akt1 Inhibits Anchorage-Independent Cell Growth and Induces Apoptosis in Cancer Cells. Neoplasia 3:4, pages 278-286.
Crossref
Salvador Aznar & Juan Carlos Lacal. 2001. 193 234 .
Ivana Gojo & Judith E. Karp. 2001. Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia. Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia 231 255 .
Saïd M Sebti & Andrew D Hamilton. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:56, pages 6584-6593.
Crossref
George C Prendergast & Allen Oliff. (2000) Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Seminars in Cancer Biology 10:6, pages 443-452.
Crossref
Janet M.D Plate, Kathryn S Petersen, Lela Buckingham, Homayoun Shahidi & Claude M Schofield. (2000) Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis. Experimental Hematology 28:11, pages 1214-1224.
Crossref
Blaine C White, Jonathon M Sullivan, Donald J DeGracia, Brian J O’Neil, Robert W Neumar, Lawrence I Grossman, José A Rafols & Gary S Krause. (2000) Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. Journal of the Neurological Sciences 179:1-2, pages 1-33.
Crossref
Elena V Rusyn, Evangeline R Reynolds, Haipeng Shao, Theresa M Grana, Tung O Chan, Douglas A Andres & Adrienne D Cox. (2000) Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Oncogene 19:41, pages 4685-4694.
Crossref
Ai-xue Liu & George C. Prendergast. (2000) Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Letters 481:3, pages 205-208.
Crossref
Hironori Edamatsu, Chia-Ling Gau, Tetsuo Nemoto, Lea Guo & Fuyuhiko Tamanoi. (2000) Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19:27, pages 3059-3068.
Crossref
Zeng Qiang Yuan, Mei Sun, Richard I Feldman, Gen Wang, Xiao-ling Ma, Chen Jiang, Domenico Coppola, Santo V Nicosia & Jin Q Cheng. (2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19:19, pages 2324-2330.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.